Last reviewed · How we verify

NCT07163299: ICE-MAG

Intra-arterial Selective Hypothermic Magnesium Sulfate Infusion in Combination With Endovascular Thrombectomy in Acute Ischemic Stroke

ENROLLING BY INVITATION Phase 1, PHASE2 Last updated 25 September 2025
What this trial tests

Phase 1, PHASE2 trial testing Endovascular thrombectomy combination with selective intra-arterial hypothermic magnesium sulfate infusion (350 ml). in Acute Ischemic Stroke in 42 participants. Enrolling by invitation.

Timeline
15 September 2025
Primary endpoint
30 December 2026
30 March 2027

Quick facts

Lead sponsorCapital Medical University
PhasePhase 1, PHASE2
StatusENROLLING BY INVITATION
Study typeINTERVENTIONAL
Allocationrandomized
Designsequential
Maskingdouble
Primary purposetreatment
Enrollment42
Start date15 September 2025
Primary completion30 December 2026
Estimated completion30 March 2027
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Capital Medical University

Who can join

Adults 18 to 80, any sex, with Acute Ischemic Stroke. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective of this study is to estimate the safety and effectiveness of selective intra-arterial hypothermic magnesium sulfate infusion after endovascular thrombectomy in patients with acute ischemic stroke

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Acute Ischemic Stroke

Currently open trials in the same condition.

Other Capital Medical University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07163299.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing